Every S-3 that PDS Biotechnology Corporation (PDSB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow PDSB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PDSB filings page.
PDS Biotechnology Corporation (PDSB) is registering for resale by selling stockholders up to 110,001,540 shares of common stock: 16,502,870 issued shares, up to 73,498,156 shares issuable under pre-funded warrants, including up to 50,000,000 tied to the Milestone Closing, and up to 20,000,514 shares issuable under common warrants. Selling stockholders may sell all, some or none, and may not sell under this prospectus until the registration statement is effective. PDSB receives no proceeds from resales; it may receive cash-exercise proceeds at $0.00033 per pre-funded warrant share and $0.22 per common warrant share, intended for working capital and general corporate purposes.
Common shares outstanding were 105,005,429 as of October 9, 2026. The pre-funded and common warrants have beneficial ownership limitations of 19.99% and 19.9%, respectively. Upon submission to the FDA of a registrational Phase 3 clinical trial protocol for PDS0301, Nant and AB Group Ltd. are obligated, subject to applicable closing conditions, to purchase additional securities for $10,000,000 and $1,000,000, respectively.
PDS Biotechnology Corporation filed a resale registration covering up to 13,315,823 shares of common stock for YA II PN, Ltd. The registered shares consist of 2,158,274 shares issuable upon exercise of a warrant and up to 11,157,549 shares issuable upon conversion of a $6,000,000 promissory note, all issued in a private placement. The company will receive no proceeds from the resale, only potential cash if the warrant is exercised, which would be used for general corporate purposes. Shares of common stock outstanding were 55,921,806 as of July 2, 2026; this is a baseline figure, not the amount being offered.
PDS Biotechnology Corporation amended its Form S-3 registration to register an aggregate initial offering price of $200,000,000 of common stock, preferred stock, debt securities, warrants, units and rights. The amendment updates Nasdaq market price information, removes a prior at-market sales agreement covering up to $20.0 million, files updated exhibits including a KPMG LLP consent, and makes related conforming changes to the prospectus.
The prospectus states the last reported Nasdaq sale price was $0.9281 per share and reports a public float of $73,989,796 based on 54,404,262 shares held by non-affiliates (price cited from April 15, 2026). Shares outstanding were 55,815,653 as of April 23, 2026.